S&P 500   3,932.61 (-0.22%)
DOW   33,594.57 (+-0.01%)
QQQ   280.03 (-0.59%)
AAPL   141.04 (-1.31%)
MSFT   244.06 (-0.43%)
META   113.77 (-0.31%)
GOOGL   95.48 (-1.55%)
AMZN   87.91 (-0.39%)
TSLA   173.01 (-3.79%)
NVDA   159.71 (-0.10%)
NIO   12.52 (-5.44%)
BABA   88.81 (-2.89%)
AMD   70.80 (+0.75%)
T   19.36 (+0.99%)
MU   53.71 (+0.06%)
CGC   3.33 (-7.76%)
F   13.30 (+0.15%)
GE   85.24 (-0.05%)
DIS   92.33 (+0.04%)
AMC   6.51 (-3.56%)
PYPL   75.12 (+4.00%)
PFE   50.45 (+1.49%)
NFLX   306.73 (+0.38%)
S&P 500   3,932.61 (-0.22%)
DOW   33,594.57 (+-0.01%)
QQQ   280.03 (-0.59%)
AAPL   141.04 (-1.31%)
MSFT   244.06 (-0.43%)
META   113.77 (-0.31%)
GOOGL   95.48 (-1.55%)
AMZN   87.91 (-0.39%)
TSLA   173.01 (-3.79%)
NVDA   159.71 (-0.10%)
NIO   12.52 (-5.44%)
BABA   88.81 (-2.89%)
AMD   70.80 (+0.75%)
T   19.36 (+0.99%)
MU   53.71 (+0.06%)
CGC   3.33 (-7.76%)
F   13.30 (+0.15%)
GE   85.24 (-0.05%)
DIS   92.33 (+0.04%)
AMC   6.51 (-3.56%)
PYPL   75.12 (+4.00%)
PFE   50.45 (+1.49%)
NFLX   306.73 (+0.38%)
S&P 500   3,932.61 (-0.22%)
DOW   33,594.57 (+-0.01%)
QQQ   280.03 (-0.59%)
AAPL   141.04 (-1.31%)
MSFT   244.06 (-0.43%)
META   113.77 (-0.31%)
GOOGL   95.48 (-1.55%)
AMZN   87.91 (-0.39%)
TSLA   173.01 (-3.79%)
NVDA   159.71 (-0.10%)
NIO   12.52 (-5.44%)
BABA   88.81 (-2.89%)
AMD   70.80 (+0.75%)
T   19.36 (+0.99%)
MU   53.71 (+0.06%)
CGC   3.33 (-7.76%)
F   13.30 (+0.15%)
GE   85.24 (-0.05%)
DIS   92.33 (+0.04%)
AMC   6.51 (-3.56%)
PYPL   75.12 (+4.00%)
PFE   50.45 (+1.49%)
NFLX   306.73 (+0.38%)
S&P 500   3,932.61 (-0.22%)
DOW   33,594.57 (+-0.01%)
QQQ   280.03 (-0.59%)
AAPL   141.04 (-1.31%)
MSFT   244.06 (-0.43%)
META   113.77 (-0.31%)
GOOGL   95.48 (-1.55%)
AMZN   87.91 (-0.39%)
TSLA   173.01 (-3.79%)
NVDA   159.71 (-0.10%)
NIO   12.52 (-5.44%)
BABA   88.81 (-2.89%)
AMD   70.80 (+0.75%)
T   19.36 (+0.99%)
MU   53.71 (+0.06%)
CGC   3.33 (-7.76%)
F   13.30 (+0.15%)
GE   85.24 (-0.05%)
DIS   92.33 (+0.04%)
AMC   6.51 (-3.56%)
PYPL   75.12 (+4.00%)
PFE   50.45 (+1.49%)
NFLX   306.73 (+0.38%)
NASDAQ:STRO

Sutro Biopharma - STRO Stock Forecast, Price & News

$7.47
+0.06 (+0.81%)
(As of 12/7/2022 11:46 AM ET)
Add
Compare
Today's Range
$7.30
$7.60
50-Day Range
$5.41
$8.04
52-Week Range
$3.33
$16.60
Volume
75,764 shs
Average Volume
373,445 shs
Market Capitalization
$429.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.67

Sutro Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
148.6% Upside
$18.67 Price Target
Short Interest
Bearish
6.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.67) to ($2.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

724th out of 1,023 stocks

Biological Products, Except Diagnostic Industry

117th out of 170 stocks

STRO stock logo

About Sutro Biopharma (NASDAQ:STRO) Stock

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STRO Stock News Headlines

Sutro Biopharma, Inc. (STRO)
Short Volatility Alert: Sutro Biopharma, Inc.
See More Headlines
Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STRO Company Calendar

Last Earnings
11/08/2022
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STRO
Fax
N/A
Employees
224
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.67
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+149.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-105,540,000.00
Net Margins
-175.85%
Pretax Margin
-172.27%

Debt

Sales & Book Value

Annual Sales
$61.88 million
Book Value
$5.46 per share

Miscellaneous

Free Float
53,222,000
Market Cap
$429.30 million
Optionable
Not Optionable
Beta
0.99

Key Executives

  • Mr. William J. Newell J.D. (Age 64)
    CEO & Director
    Comp: $1.06M
  • Mr. Edward C. Albini (Age 64)
    CFO & Sec.
    Comp: $596.4k
  • Dr. Trevor J. Hallam (Age 63)
    Pres of Research & Chief Scientific Officer
    Comp: $882.83k
  • Dr. Arturo M. Molina FACP (Age 63)
    M.D., M.S., MS, Chief Medical Officer
    Comp: $691.83k
  • Ms. Jane Chung R.Ph. (Age 51)
    Chief Commercial Officer
    Comp: $832.52k
  • Dr. James R. Swartz Ph.D.
    Sc.D., Founder
  • Dr. Shabbir T. Anik (Age 69)
    Chief Technical Operations Officer
  • Ms. Annie J. Chang M.B.A.
    VP of Investor Relations
  • Mr. David Pauling J.D.
    M.A., Gen. Counsel
  • Ms. Linda A. Fitzpatrick (Age 65)
    Chief People & Communications Officer













STRO Stock - Frequently Asked Questions

Should I buy or sell Sutro Biopharma stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STRO shares.
View STRO analyst ratings
or view top-rated stocks.

What is Sutro Biopharma's stock price forecast for 2023?

5 brokerages have issued twelve-month price objectives for Sutro Biopharma's stock. Their STRO share price forecasts range from $15.00 to $21.00. On average, they anticipate the company's stock price to reach $18.67 in the next twelve months. This suggests a possible upside of 151.9% from the stock's current price.
View analysts price targets for STRO
or view top-rated stocks among Wall Street analysts.

How have STRO shares performed in 2022?

Sutro Biopharma's stock was trading at $14.88 at the beginning of the year. Since then, STRO shares have decreased by 50.2% and is now trading at $7.41.
View the best growth stocks for 2022 here
.

When is Sutro Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our STRO earnings forecast
.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) released its earnings results on Tuesday, November, 8th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.22. The firm earned $25.15 million during the quarter, compared to the consensus estimate of $11.35 million. Sutro Biopharma had a negative net margin of 175.85% and a negative trailing twelve-month return on equity of 53.85%.

What is William J. Newell's approval rating as Sutro Biopharma's CEO?

11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV).

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Sutro Biopharma's stock symbol?

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.97%), Vanguard Group Inc. (3.57%), Baillie Gifford & Co. (3.58%), Rubric Capital Management LP (2.44%), Verition Fund Management LLC (2.18%) and State Street Corp (1.44%). Insiders that own company stock include Arturo Md Molina, John Gordon Freund, Nicki Vasquez, Trevor Hallam and William J Newell.
View institutional ownership trends
.

How do I buy shares of Sutro Biopharma?

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sutro Biopharma's stock price today?

One share of STRO stock can currently be purchased for approximately $7.41.

How much money does Sutro Biopharma make?

Sutro Biopharma (NASDAQ:STRO) has a market capitalization of $425.89 million and generates $61.88 million in revenue each year. The company earns $-105,540,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis.

How many employees does Sutro Biopharma have?

The company employs 224 workers across the globe.

How can I contact Sutro Biopharma?

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The official website for the company is www.sutrobio.com. The company can be reached via phone at (650) 392-8412 or via email at ajchang@sutrobio.com.

This page (NASDAQ:STRO) was last updated on 12/7/2022 by MarketBeat.com Staff